Webform

U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

FOR IMMEDIATE RELEASE

MEDIA CONTACT:

Scott Meeks scott@zerocancer.org

Washington, D.C., Aug. 05, 2022 – Bayer announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) with docetaxel for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).1 Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall survival (OS) benefit with NUBEQA plus androgen deprivation therapy (ADT) and docetaxel compared to ADT and docetaxel1 NUBEQA is the only androgen receptor inhibitor (ARi) approved in combination with docetaxel for mHSPC, demonstrating a 32% reduction in the risk of death compared to docetaxel alone and with a proven tolerability profile1

Read the full press release here.

References

  1. NUBEQA® (darolutamide) tablets [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, August 2022.
Share

Androgen

Hormones found in men and women but with much higher levels in men; commonly called male sex hormones. The major androgen is testosterone.

mHSPC

Metastatic Hormone-Sensitive Prostate Cancer is cancer that has spread outside of the prostate and can still be treated with hormone therapy. This may also be called Metastatic Castration-Sensitive Prostate Cancer (mCSPC).

Sign Up for Our Newsletter!

Stay connected with ZERO Prostate Cancer through our newsletter below: